Trial ID 21239 | Maryland Oncology Hematology Trial ID 21239 – Maryland Oncology Hematology

Trial ID 21239

Trial Information - Phase III

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Disease Specifics: NSCLC

Protocol ID: 61186372NSC3002

Sponsor: Jannsen

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Status

STAR Trial

Sponsor

Jannsen

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology